The Readout Loud
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.